RTP Mobile Logo

SABCS14

SURVEY PARTICIPANTS
Kathy S Albain, MD
Kimberly L Blackwell, MD
Howard A Burris III, MD
Harold J Burstein, MD, PhD
Lisa A Carey, MD
Rowan T Chlebowski, MD, PhD
Javier Cortes, MD, PhD
Kevin R Fox, MD
Julie R Gralow, MD
Daniel F Hayes, MD
Clifford Hudis, MD
Sara A Hurvitz, MD
Ian E Krop, MD, PhD
Hannah M Linden, MD
John Mackey, MD
Kathy D Miller, MD
Hyman B Muss, MD
Ruth O’Regan, MD
Joyce O’Shaughnessy, MD
Hope S Rugo, MD
Andrew D Seidman, MD
George W Sledge Jr, MD
Ian E Smith, MD
Joseph A Sparano, MD
Sunil Verma, MD, MSEd

ASH13

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

Beyond the Guidelines 2013

Breast Cancer Investigator Survey | SABCS 2013

Consensus Or Controversy 2013

Consensus or Controversy NHL/CLL

Use T-DM1 + pert off protocol? Use pert as 2nd- or later-line Tx?

Are there situations in which you would use T-DM1 combined with pertuzumab outside of a trial?

If a patient had not received pertuzumab in the first-line setting, would you use it in the second line or beyond? If so, in what situations would you use it?

Initial Tx asym. 60 yo, ER+/HER2+, liver, lung mets? Sym. pt?

What initial first-line systemic therapy would you generally recommend for an asymptomatic 60-year-old patient with ER-positive, HER2-positive breast cancer and documented liver and lung metastases who has received no prior therapy? The same patient but symptomatic?

Initial Tx asym. 60 yo, ER+/HER2+, bone mets? Sym. pt?

What initial first-line systemic therapy, other than bone-directed treatment, would you generally recommend for an asymptomatic 60-year-old patient with ER-positive, HER2-positive breast cancer and several documented bone metastases who has received no prior therapy? The same patient but symptomatic?

1st-line Tx HER2+/ER-neg untreated mBC? 2nd-line Tx HER2+/ER-neg mBC?

What is your usual first-line treatment for patients with HER2-positive, ER-negative metastatic disease who have received no prior therapy?

What is your usual second-line treatment for patients with HER2-positive, ER-negative metastatic disease?

Use T-DM1 + pert off protocol? If not used in 1st line, use pert as 2nd/later-line Tx?

Are there situations in which you would use T-DM1 combined with pertuzumab outside of a trial?

If a patient had not received pertuzumab in the first-line setting, would you use it in the second line or beyond? If so, in what situations would you use it?

Consensus Or Controversy 2013

Consensus or Controversy MM

Initial Tx asym. 60 yo, ER+/HER2+, liver, lung mets? Sym. pt?

What initial first-line systemic therapy would you generally recommend for an asymptomatic 60-year-old patient with ER-positive, HER2-positive breast cancer and documented liver and lung metastases who has received no prior therapy? The same patient but symptomatic?

Consensus or Controversy, Issue 4: Clinical Investigators Provide Their Perspectives on Controversial Issues in the Treatment of HER2-Positive Metastatic Breast Cancer

COCB13/4/CME

TARGET AUDIENCE
This activity is intended for medical oncologists, hematologist-oncologists, hematology-oncology fellows, oncology nurses, radiation oncologists, breast/general surgeons and other healthcare practitioners involved in the management of breast cancer.

OVERVIEW OF ACTIVITY
Breast cancer remains the most frequently diagnosed type of cancer in women, with an estimated 234,580 new cases and 40,030 deaths in the United States in 2013. Advances in screening and prevention have resulted in a steady down-stage migration at the time of disease presentation, and the number of individuals living with breast cancer has increased substantially, as has the population “at risk” for recurrent disease.

Striving for Consensus: The Application of Existing and Emerging Research Findings to the Practical Management of Hodgkin and Non-Hodgkin Lymphoma

Striving for Consensus: The Application of Existing and Emerging Research Findings to the Practical Management of Hodgkin and Non-Hodgkin Lymphoma